摘要
目的分析丙戊酸钠联合利培酮或喹硫平对伴攻击行为精神分裂症患者的治疗效果及不良反应情况。方法将2020年8月至2022年8月驻马店第二人民医院116例伴攻击行为精神分裂症患者随机分为对照组及观察组(n=58)。对照组采用丙戊酸钠联合喹硫平治疗,观察组采用丙戊酸钠联合利培酮治疗。比较两组患者疗效、简明精神病评定量表(BPRS)评分、外显攻击行为量表(MOAS)评分、血清神经营养因子水平及安全性。结果观察组治疗总有效率(82.76%)与对照组治疗总有效率(77.59%)无显著差异(P>0.05)。治疗后两组BPRS及MOAS评分均降低,且观察组显著低于对照组(P<0.05)。治疗后两组患者脑源性神经营养因子(BDNF)及胶质细胞源性神经营养因子(GDNF)水平与治疗前相比均升高,但治疗后两组患者BDNF及GDNF水平差异无统计学意义(P>0.05)。对照组不良反应发生率为31.03%,观察组不良反应发生率为37.93%,两组无显著差异(P>0.05)。结论丙戊酸钠与利培酮或喹硫平联合对伴攻击行为精神分裂症患者均有确切疗效,且不良反应较少,安全性高,值得临床推广。
Objective To analyze the efficacy and adverse reactions of sodium valproate combined with risperidone or quetiapine on schizophrenia cases with aggressive behavior.Methods A total of 116 patients with schizophrenia with ag⁃gressive behavior in Zhumadian Second People’s Hospital from August 2020 to August 2022 were randomly divided into control group and observation group(n=58).The patients in control group were treated with sodium valproate combined with quetiapine,and the patients in observation group were treated with sodium valproate and risperidone.Efficacy,Brief Psychiatric Rating Scale(BPRS)score,Modified Overt Aggression Scale(MOAS)score,serum neurotrophic fac⁃tor levels,and safety were analyzed.Results The total effective rate between the observation group(82.76%)and the control group(77.59%)had no significant difference(P>0.05).After treatment,the BPRS and MOAS scores in both groups were decreased,and the scores in observation group were significantly lower than control group(P<0.05).After treatment,the levels of brain derived neurotrophic factor(BDNF)and glial cell derived neurotrophic factor(GD⁃NF)in 2 groups were increased compared with before treatment,but there was no statistical significance in the levels of BDNF and GDNF in 2 groups after treatment(P>0.05).The incidence of adverse reactions was 31.03%in control group and 37.93%in observation group,and there was no statistical significance between the two groups(P>0.05).Conclusion The combination of sodium valproate with risperidone or quetiapine had a definite effect on schizophrenia patients with aggressive behavior,with few adverse reactions,high safety and worthy of clinical promotion.
作者
孟祥宇
赵顺来
王华真
张腾
黄群群
MENG Xiang-yu;ZHAO Shun-lai;WANG Hua-zhen;ZHANG Teng;HUANG Qun-qun(Pharmacy Department of the Second People's Hospital of Zhumadian,Henan 463000,China;The Ninth Department of Psychiatry,the Second People's Hospital of Zhumadian,Henan 463000,China;Substance dependence Department of the Second People's Hospital of Zhumadian,Henan 463000,China;The Second Department of Child and Juvenile Psychology of the Second People's Hospital of Zhumadian,Henan 463000,China)
出处
《医药论坛杂志》
2023年第24期90-93,共4页
Journal of Medical Forum
关键词
丙戊酸钠
利培酮
喹硫平
精神分裂症
攻击行为
不良反应
Sodium valproate
Risperidone
Quetiapine
Schizophrenia
Aggressive behavior
Adverse reactions
